How to buy Meridian Bioscience stock

Meridian Bioscience, Inc is a diagnostics & research business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars. Meridian Bioscience employs 750 staff and has a trailing 12-month revenue of around 0.00.

Meridian Bioscience share price

Use our graph to track the performance of VIVO stocks over time.

Meridian Bioscience shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$10.65 - $30.65
50-day moving average	$24.49
200-day moving average	$21.58
Wall St. target price	$32.67
PE ratio	13.9727
Dividend yield	$0 (0%)
Earnings per share (TTM)	$1.61

Buy Meridian Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Meridian Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Meridian Bioscience, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Meridian Bioscience under- or over-valued?

Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Meridian Bioscience's P/E ratio

Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Meridian Bioscience shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Meridian Bioscience's PEG ratio

Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Meridian Bioscience's EBITDA

Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $105.8 million.

The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.

Meridian Bioscience financials

Revenue TTM	$299.2 million
Operating margin TTM	30.57%
Gross profit TTM	$156.2 million
Return on assets TTM	15%
Return on equity TTM	29.46%
Profit margin	23.45%
Book value	$6.47
Market capitalisation	$971.2 million

TTM: trailing 12 months

Shorting Meridian Bioscience shares

There are currently 4.1 million Meridian Bioscience shares held short by investors – that's known as Meridian Bioscience's "short interest". This figure is 16.1% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Meridian Bioscience shares can be evaluated.

Meridian Bioscience's "short interest ratio" (SIR)

Meridian Bioscience's "short interest ratio" (SIR) is the quantity of Meridian Bioscience shares currently shorted divided by the average quantity of Meridian Bioscience shares traded daily (recently around 822661.35458167). Meridian Bioscience's SIR currently stands at 5.02. In other words for every 100,000 Meridian Bioscience shares traded daily on the market, roughly 5020 shares are currently held short.

However Meridian Bioscience's short interest can also be evaluated against the total number of Meridian Bioscience shares, or, against the total number of tradable Meridian Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Meridian Bioscience's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Meridian Bioscience shares in existence, roughly 100 shares are currently held short) or 0.1317% of the tradable shares (for every 100,000 tradable Meridian Bioscience shares, roughly 132 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Meridian Bioscience.

Find out more about how you can short Meridian Bioscience stock.

Meridian Bioscience share dividends

We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.

Have Meridian Bioscience's shares ever split?

Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.

Meridian Bioscience share price volatility

Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $10.65 up to $30.65. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.5985. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).

Meridian Bioscience overview

Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H.

Frequently asked questions

• What percentage of Meridian Bioscience is owned by insiders or institutions?

  Currently 0.546% of Meridian Bioscience shares are held by insiders and 103.999% by institutions.

• How many people work for Meridian Bioscience?

  Latest data suggests 750 work at Meridian Bioscience.

• When does the fiscal year end for Meridian Bioscience?

  Meridian Bioscience's fiscal year ends in September.

• Where is Meridian Bioscience based?

  Meridian Bioscience's address is: 3471 River Hills Drive, Cincinnati, OH, United States, 45244

• What is Meridian Bioscience's ISIN number?

  Meridian Bioscience's international securities identification number is: US5895841014

• What is Meridian Bioscience's CUSIP number?

  Meridian Bioscience's Committee on Uniform Securities Identification Procedures number is: 589584101